| Literature DB >> 24349340 |
Cheng-Hao Weng1, Ching-Chih Hu2, Ja-Liang Lin1, Dan-Tzu Lin-Tan1, Ching-Wei Hsu1, Tzung-Hai Yen1.
Abstract
INTRODUCTION: Paraquat poisoning is characterized by acute lung injury, pulmonary fibrosis, respiratory failure, and multi-organ failure, resulting in a high rate of mortality and morbidity. The objectives of this study were to identify predictors of acute respiratory distress syndrome (ARDS) in cases of paraquat poisoning and determine the association between these parameters.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24349340 PMCID: PMC3859634 DOI: 10.1371/journal.pone.0082695
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Baseline demographics and clinical characteristics of paraquat patients with and without ARDS (n=187).
| Parameter | All patients (n=187) | ARDS patients (n=50) | Non-ARDS patients (n=137) |
|
|---|---|---|---|---|
| Age | 42.1±15.40 | 40.56±15.18 | 42.58±15.60 | 0.439 |
| Gender (male/female) | 144/43 | 38/12 | 106/31 | 1.000 |
| Mortality n (%) | 100 (53.48) | 40 (80) | 60 (43.80) | <0.001*** |
| Hemoperfusion n (%) | 167 (89.30) | 45 (90) | 122 (89.05) | 0.785 |
| Time to hospitalization (hours) | 13.49±21.13 | 11.45±20.29 | 14.22±21.57 | 0.438 |
| Estimated ingestion amount (mL) | 80.91±104.68 | 92.81±90.411 | 77.11±109.90 | 0.375 |
| Blood paraquat concentration (ppm) | 4.77±5.61 | 5.80±6.46 | 4.32±5.13 | 0.110 |
| Urine paraquat concentration (ppm) | 37.78±18.70 | 41.68±15.57 | 36.23±19.62 | 0.055 |
| Peak AST concentration (U/L) | 125.06±139.20 | 101.40±71.95 | 136.33±162.24 | 0.523 |
| Peak ALT concentration (U/L) | 183.20±121.03 | 232.54±258.63 | 160.29±135.74 | 0.100 |
| Peak bilirubin concentration (mg/dL) | 3.17±1.69 | 3.58±4.18 | 2.61±3.21 | 0.388 |
| AKIN 48-h (stage 0/1/2/3) | 98/49/17/23 | 20/11/7/12 | 78/38/10/11 | 0.009** |
| SOFA 48-h | 3.15±2.3 | 5.10±2.16 | 2.47±1.96 | <0.001** |
| Time to ARDS (ARDS patients) or time to nadir PaO2 (Non-ARDS paients) (days) | 7.40±8.02 | 10.04±9.01 | 6.47±7.52 | 0.008** |
| nadir PaO2 | 61.28±24.99 | 30.21±7.60 | 72.16±19.10 | <0.001*** |
| nadir AaDO2 | 46.62±28.34 | 75.03±26.03 | 36.66±21.90 | <0.001*** |
| nadir eGFR | 57.05±33.38 | 43.52±21.47 | 62.12±35.49 | 0.001** |
| Pneumomediastinum (n) (%) | 7 (3.7%) | 5 (10%) | 2 (1.5%) | <0.001*** |
| Pneumothorax (n) (%) | 1 (0.5%) | 0 | 1 (2%) |
Note: AaDO2 alveolar-arterial oxygen gradient, AKIN Acute Kidney Injury Network, ALT alanine aminotransferase, ARDS acute respiratory distress syndrome, AST aspartate aminotransferase, eGFR estimated glomerular filtration rate, PaO2 partial pressure of oxygen in arterial blood, SOFA Sequential Organ Failure Assessment, *P<0.05, **P<0.01, ***P<0.001
Comparison of calibration and discrimination power of SOFA scoring methods for predicting ARDS (n=187).
| Calibration | Discrimination | |||||
|---|---|---|---|---|---|---|
| Hosmer-Lemeshow goodness of fit |
|
| AUROC±SE | 95% CI |
| |
| Blood paraquat concen- tration (PPM) | 8.463 | 7 | 0.294 | 0.622±0.045 | 0.534-0.711 | 0.01* |
| SOFA48-h | 6.818 | 5 | 0.235 | 0.827±0.030 | 0.769-0.886 | <0.001*** |
Note: AUROC area under receiver operating characteristic CI confidence interval, df degree of freedom, SE standard error, SOFA sequential organ failure assessment, *P<0.05, ***P<0.001
Analysis of mortality using univariate and multivariate Cox regression models (n = 187).
| B | SE | Exp(B) |
| |
|---|---|---|---|---|
|
| ||||
| Time to hospital (hours) | -0.019 | 0.009 | 0.983 (0.964-0.998) | 0.026* |
| Estimated ingestion amount (mL) | 0.004 | 0.001 | 1.004 (1.001-1.007) | 0.006** |
| Steroid and cyclophosphamide pulse therapies | -1.029 | 0.530 | 0.357 (0.127-0.996) | 0.048* |
| Blood paraquat concentration (ppm) | 0.156 | 0.026 | 1.169 (1.111-1.231) | <0.001*** |
| eGFR (ml/min) | -0.018 | 0.006 | 0.982 (0.970-0.994) | 0.004** |
| SOFA48-h | 0.215 | 0.052 | 1.240 (1.120-1.372) | <0.001*** |
|
| ||||
| Blood paraquat concentration (ppm) | 0.135 | .027 | 1.145 (1.086-1.208) | <0.001*** |
| SOFA48-h | 0.182 | 0.057 | 1.200 (1.074-1.341) | 0.001** |
| Pulse therapy | -1.239 | 0.548 | 0.290 (0.099-0.849) | 0.024* |
Note: eGFR estimated glomerular filtration rate, SOFA Sequential Organ Failure Assessment, *P<0.05, **P<0.01, ***P<0.001
Prediction of ARDS (n=187).
| Predictive factors | Cutoff point | Youden index | Sensitivity % | Specificity % | Overall correctness % |
|---|---|---|---|---|---|
| Blood paraquat concentration (PPM) | 1 | 0.312 | 61.4 | 69.8 | 54.0 |
| SOFA48-h | 3 | 0.542 | 95.8 | 58.4 | 67.6 |
SOFA: sequential organ failure assessment
Figure 1Cumulative ARDS free rates based on SOFA 48-h score.
SOFA scoring system.
| 0 | 1 | 2 | 3 | 4 | |
|---|---|---|---|---|---|
| PaO2/FiO2 | >400 | 301–400 | 201–300 | 101–200 with respiratory support | ≤ 100 with respiratory support |
| Platelets (1000/µL) | >150 | 101–150 | 51–100 | 21–50 | ≤20 |
| Bilirubin (mg/dL) | <1.2 | 1.2–1.9 | 2.0–5.9 | 6.0–11.9 | >12.0 |
| Hypotension | MAP ≥ 70 mmHg | MAP < 70 mmHg | Dopamine 5 or dobutamine (any dose) | Dopamine >5 or epi ≤ 0.1 or norepi ≤ 0.1 | Dopamine >15 or epi >0.1 or norepi >0.1 |
| GCS | 15 | 13–14 | 10–12 | 6–9 | <6 |
| Cr (mg/dL) or UO | <1.2 | 1.2–1.9 | 2.0–3.4 | 3.5–4.9 or <500 mL/d | >5.0 or <200 mL/d |
* Adrenergic agents administered for at least 1 h (doses are given in µg/kg per minute). Abbreviations. PaO2: partial pressure of oxygen in arterial blood, FiO2: fractional inspired oxygen, MAP: mean arterial pressure, epi: epinephrine, norepi: norepinephrine, GCS: Glasgow Coma Scale score, Cr: creatinine, UO: urine output
AKIN scoring system.
| Category | Serum Cr criteria | Urine output criteria |
|---|---|---|
| Stage 1 | Increase in serum Cr of ≥0.3 mg/dL or increase to ≥150% to 200% (1.5 to 2-fold) from baseline | < 0.5 mL/kg/h for more than 6 h |
| Stage 2 | Increase in serum Cr to >200% to 300% (>2 to 3-fold) from baseline | < 0.5 mL/kg/h for more than 12 h |
| Stage 3 | Increase in serum Cr to >300% (3-fold) from baseline (or serum Cr of ≥4.0 mg/dL with an acute increase of at least 0.5 mg/dL | < 0.3 mL/kg/h for 24 h or anuria more for 12 h |
Cr: creatinine